D.E. Shaw & Co
PROF

D.E. Shaw & Co’s Profound Medical PROF Stock Holding History

D.E. Shaw & Co’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22,148
Closed -$199K – 5685
2022
Q1 		$199K Buy
22,148
+11,433
+107% +$110K ﹤0.01% 4871
2021
Q4 		$121K Buy
+10,715
New +$134K ﹤0.01% 5023

Other funds holding PROF

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

D.E. Shaw & Co's PROF Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Profound Medical (PROF) in Q2 2022, closing a stake of 22,148 shares — an estimated $199K sold.

D.E. Shaw & Co first reported a position in PROF in Q4 2021 and held it in 2 quarters. The position peaked at $199K in Q1 2022. 39 funds tracked by Wall St. Rank hold PROF as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Profound Medical position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 22,148 Profound Medical shares in Q2 2022, an estimated $199K.
  • D.E. Shaw & Co first reported a position in Profound Medical in Q4 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Profound Medical position peaked at $199K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Profound Medical as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.